BEAM Quote, Financials, Valuation and Earnings

The Cooper Companies has a net margin of -1462.79% compared to Beam Therapeutics's net margin of 8.75%. Beam Therapeutics's return on equity of -43.86% beat The Cooper Companies's return on equity of 5.15%.

Beam Therapeutics has a consensus price target of $44.07, signalling upside risk potential of 119.57%. On the other hand The Cooper Companies has an analysts' consensus of $92.09 which suggests that it could grow by 26.67%. Given that Beam Therapeutics has higher upside potential than The Cooper Companies, analysts believe Beam Therapeutics is more attractive than The Cooper Companies.

Beam Therapeutics has a beta of 2.076, which suggesting that the stock is 107.573% more volatile than S&P 500. In comparison The Cooper Companies has a beta of 0.985, suggesting its less volatile than the S&P 500 by 1.451%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Companies offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Beam Therapeutics pays -- of its earnings as a dividend. The Cooper Companies pays out -- of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $7.5M, which are smaller than The Cooper Companies quarterly revenues of $1B. Beam Therapeutics's net income of -$109.3M is lower than The Cooper Companies's net income of $87.7M. Notably, Beam Therapeutics's price-to-earnings ratio is -- while The Cooper Companies's PE ratio is 35.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 26.48x versus 3.66x for The Cooper Companies. Usually stocks with elevated PS ratios are considered overvalued.

908 Devices has a net margin of -1462.79% compared to Beam Therapeutics's net margin of -103.33%. Beam Therapeutics's return on equity of -43.86% beat 908 Devices's return on equity of -12.31%.

Beam Therapeutics has a consensus price target of $44.07, signalling upside risk potential of 119.57%. On the other hand 908 Devices has an analysts' consensus of $5.50 which suggests that it could fall by -17.54%. Given that Beam Therapeutics has higher upside potential than 908 Devices, analysts believe Beam Therapeutics is more attractive than 908 Devices.

Beam Therapeutics has a beta of 2.076, which suggesting that the stock is 107.573% more volatile than S&P 500. In comparison 908 Devices has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 908 Devices offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics pays -- of its earnings as a dividend. 908 Devices pays out -- of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $7.5M, which are smaller than 908 Devices quarterly revenues of $11.8M. Beam Therapeutics's net income of -$109.3M is lower than 908 Devices's net income of $43.6M. Notably, Beam Therapeutics's price-to-earnings ratio is -- while 908 Devices's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 26.48x versus 3.77x for 908 Devices. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics has a net margin of -1462.79% compared to Beam Therapeutics's net margin of -687.61%. Beam Therapeutics's return on equity of -43.86% beat Intellia Therapeutics's return on equity of -56.9%.

Beam Therapeutics has a consensus price target of $44.07, signalling upside risk potential of 119.57%. On the other hand Intellia Therapeutics has an analysts' consensus of $37.11 which suggests that it could grow by 210.29%. Given that Intellia Therapeutics has higher upside potential than Beam Therapeutics, analysts believe Intellia Therapeutics is more attractive than Beam Therapeutics.

Beam Therapeutics has a beta of 2.076, which suggesting that the stock is 107.573% more volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.211, suggesting its more volatile than the S&P 500 by 121.143%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $7.5M, which are smaller than Intellia Therapeutics quarterly revenues of $16.6M. Beam Therapeutics's net income of -$109.3M is higher than Intellia Therapeutics's net income of -$114.3M. Notably, Beam Therapeutics's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 26.48x versus 26.47x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of -1462.79% compared to Beam Therapeutics's net margin of -93.48%. Beam Therapeutics's return on equity of -43.86% beat Viatris's return on equity of -20.24%.

Beam Therapeutics has a consensus price target of $44.07, signalling upside risk potential of 119.57%. On the other hand Viatris has an analysts' consensus of $11.3875 which suggests that it could grow by 25.41%. Given that Beam Therapeutics has higher upside potential than Viatris, analysts believe Beam Therapeutics is more attractive than Viatris.

Beam Therapeutics has a beta of 2.076, which suggesting that the stock is 107.573% more volatile than S&P 500. In comparison Viatris has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.435%.

Beam Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.29% to investors and pays a quarterly dividend of $0.12 per share. Beam Therapeutics pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

Beam Therapeutics quarterly revenues are $7.5M, which are smaller than Viatris quarterly revenues of $3.3B. Beam Therapeutics's net income of -$109.3M is higher than Viatris's net income of -$3B. Notably, Beam Therapeutics's price-to-earnings ratio is -- while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics is 26.48x versus 0.76x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.